This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).
1 Primary · 5 Secondary · Reporting Duration: Week 12
Experimental Treatment
Non-Treatment Group
675 Total Participants · 3 Treatment Groups
Primary Treatment: BLU-5937 50 mg · Has Placebo Group · Phase 3
Age 18 - 80 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Texas | 100.0% |
Did not meet criteria | 100.0% |
0 | 50.0% |
3+ | 50.0% |